A
Ashish Juvekar
Researcher at Beth Israel Deaconess Medical Center
Publications - 11
Citations - 980
Ashish Juvekar is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 5, co-authored 9 publications receiving 796 citations.
Papers
More filters
Journal ArticleDOI
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Ashish Juvekar,Laura N. Burga,Hai Hu,Elaine P. Lunsford,Yasir H. Ibrahim,Judith Balmaña,Anbazhagan Rajendran,Antonella Papa,Katherine Spencer,Costas A. Lyssiotis,Caterina Nardella,Pier Paolo Pandolfi,José Baselga,Ralph Scully,John M. Asara,Lewis C. Cantley,Gerburg M. Wulf +16 more
TL;DR: The combination of a PI3K inhibitor with a PARP inhibitor provides in vivo synergy for treatment of an endogenous mouse model for BRCA1-related breast cancers, making this a candidate combination to be tested in human clinical trials.
Journal ArticleDOI
Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton
Hai Hu,Ashish Juvekar,Costas A. Lyssiotis,Evan C. Lien,John G. Albeck,Doogie Oh,Gopal Varma,Yin P Hung,Soumya Ullas,Josh Lauring,Pankaj Seth,Mark R. Lundquist,Dean R. Tolan,Aaron K. Grant,Daniel J. Needleman,John M. Asara,Lewis C. Cantley,Gerburg M. Wulf +17 more
TL;DR: A master regulatory function of PI3K is pointed toward that integrates an epithelial cell's metabolism and its form, shape, and function, coordinating glycolysis with the energy-intensive dynamics of actin remodeling.
Journal ArticleDOI
Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer
Evan C. Lien,Costas A. Lyssiotis,Ashish Juvekar,Hai Hu,John M. Asara,Lewis C. Cantley,Alex Toker +6 more
TL;DR: In mammary epithelial cells, oncogenic PI(3)K/Akt stimulates glutathione (GSH) biosynthesis by stabilizing and activating NRF2 to upregulate the GSH biosynthetic genes, providing insight into G SH biosynthesis as a metabolic vulnerability associated with PI( 3)K pathway mutant breast cancers.
Journal ArticleDOI
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
Ashish Juvekar,Hai Hu,Sina Yadegarynia,Costas A. Lyssiotis,Soumya Ullas,Evan C. Lien,Gary Bellinger,Jaekyoung Son,Rosanna C. Hok,Pankaj Seth,Michele B. Daly,Baek Kim,Ralph Scully,John M. Asara,Lewis C. Cantley,Gerburg M. Wulf +15 more
TL;DR: It is shown that enhanced DNA damage induced by PI3K inhibitors in this mutational background is a consequence of impaired production of nucleotides needed for DNA synthesis and DNA repair.
Journal ArticleDOI
Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1 -mutant mice
TL;DR: It is proposed that even partial loss of BRCA1 leads to an overall increase in EGFR expression in MECs and to an expansion of the highly EGFR-expressing, ALDH1-positive fraction.